Physician profile
Michael A Murillo
NPI 1316332620
$286.55
in general payments reported to CMS, 2019-2025
9 companies · $52.75 in 2025
The $52.75 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.62 · 2022: $43.75 · 2023: $58.25 · 2024: $79.18 · 2025: $52.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $190.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $79.61 | 2021-2024 | Eliquis, Camzyos |
| Pfizer INC. | $67.78 | 2023-2025 | |
| Inari Medical, INC. | $28.80 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.11 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.58 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $16.50 | 2022 | |
| Chiesi USA, INC. | $15.65 | 2025 | Cleviprex |
| Astrazeneca Pharmaceuticals LP | $14.92 | 2022 | |
| Merck Sharp & Dohme LLC | $13.60 | 2024 | Zerbaxa, Recarbrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Murillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.